Casi Pharmaceuticals Inc (CASI) Stock Price, Quote & News

Company Profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investiga...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 10 6508 6063

Website: www.casipharmaceuticals.com

Address:

1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Chaoyang District, Beijing, China

DARKP00L Sep. 8 at 2:06 PM

$CASI 09:14 on Sep. 08 2025 Casi Pharmaceuticals Completes Review Of Cohort 4 In The Phase 1 Trial Of CID-103 For Chronic Immune Thrombocytopenia And Found No Safety Concerns And Recommends Trial Continue With Dose Escalation To Cohort 5 As Planned. #tradeideas

0 · Reply

DARKP00L Sep. 8 at 2:06 PM

$CASI 09:14 on Sep. 08 2025 CASI Pharmaceuticals Advances Anti-CD38 Antibody CID-103 To Next Dose Cohort In Phase 1 ITP Trial #tradeideas

0 · Reply

JarvisFlow Sep. 3 at 11:30 AM

HC Wainwright & Co. updates rating for CASI Pharmaceuticals ( $CASI ) to Buy, target set at 4.

0 · Reply

BioTuesdays Sep. 2 at 5:07 PM

$CASI has announced the appointment of Barbara Krebs-Pohl, PhD, as an independent director to its board of directors (BOD). https://biotuesdays.com/2025/09/02/dr-barbara-krebs-pohl-joins-casis-bod/

0 · Reply

V9RDPUMA Aug. 31 at 12:49 PM

$CASI Is this now a US based company? Weren’t they Cayman Islands based? SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended June 30, 2025 (the "second quarter").

0 · Reply

TM555 Aug. 29 at 3:45 PM

$CASI predictable …

0 · Reply

TM555 Aug. 28 at 5:37 PM

$CASI hoping to see $3 soon

0 · Reply

SPYmyQQQ Aug. 28 at 2:06 PM

🚨 New Signal ✅ 💊 $CASI 🗓️ Aug 28, 2025 🎯 Entry: $2.3100 🎯 Target: $2.7667 (+19.77%)

0 · Reply

NakiaNodes Aug. 23 at 8:28 AM

$CASI CASI Pharmaceuticals Inc is facing commercialization challenges and regulatory uncertainty

0 · Reply

fromtheothersid3 Aug. 22 at 6:10 PM

$CASI 3,20 plus next week imho ☺️

0 · Reply

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Sep 3, 2025, 9:00 AM EDT - 9 days ago

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 9:00 AM EDT - 10 days ago

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

Aug 29, 2025, 4:05 PM EDT - 14 days ago

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

Aug 28, 2025, 9:00 AM EDT - 15 days ago

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Aug 4, 2025, 9:00 AM EDT - 5 weeks ago

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

Jul 21, 2025, 4:05 PM EDT - 7 weeks ago

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

May 19, 2025, 9:00 AM EDT - 4 months ago

CASI Pharmaceuticals Provides Business and Clinical Update

May 16, 2025, 8:00 AM EDT - 4 months ago

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

May 12, 2025, 8:00 AM EDT - 4 months ago

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

May 7, 2025, 8:00 AM EDT - 4 months ago

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

Apr 3, 2025, 8:00 AM EDT - 5 months ago

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

Mar 31, 2025, 8:15 AM EDT - 5 months ago

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

Jan 6, 2025, 8:00 AM EST - 8 months ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

Nov 15, 2024, 8:00 AM EST - 10 months ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Oct 24, 2024, 8:00 AM EDT - 11 months ago

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Sep 4, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Aug 16, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Jul 19, 2024, 5:30 PM EDT - 1 year ago

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Jul 8, 2024, 7:30 AM EDT - 1 year ago

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Jun 26, 2024, 4:15 PM EDT - 1 year ago

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

Jun 26, 2024, 4:10 PM EDT - 1 year ago

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

May 15, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

May 14, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

$CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China$

Mar 5, 2024, 7:00 AM EST - 1 year ago

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

Feb 16, 2024, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

Nov 14, 2023, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Nov 8, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

Aug 11, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Jul 20, 2023, 8:00 AM EDT - 2 years ago

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

May 17, 2023, 7:35 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

Apr 26, 2023, 9:49 AM EDT - 2 years ago

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Apr 26, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Mar 21, 2023, 4:30 PM EDT - 2 years ago

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Jan 6, 2023, 8:42 AM EST - 2 years ago

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Jan 6, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

Dec 15, 2022, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Nov 14, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

Sep 23, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

Sep 9, 2022, 10:32 AM EDT - 3 years ago

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

LDI TERN

Sep 7, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

Aug 29, 2022, 8:58 AM EDT - 3 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

HCWB HSDT

Aug 12, 2022, 12:28 PM EDT - 3 years ago

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript

Aug 12, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

Aug 5, 2022, 8:38 AM EDT - 3 years ago

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

Jul 8, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

Jun 2, 2022, 6:34 AM EDT - 3 years ago

CASI Pharmaceuticals stock falls after reverse split takes effect

DARKP00L Sep. 8 at 2:06 PM

0 · Reply

DARKP00L Sep. 8 at 2:06 PM

$CASI 09:14 on Sep. 08 2025 CASI Pharmaceuticals Advances Anti-CD38 Antibody CID-103 To Next Dose Cohort In Phase 1 ITP Trial #tradeideas

0 · Reply

JarvisFlow Sep. 3 at 11:30 AM

HC Wainwright & Co. updates rating for CASI Pharmaceuticals ( $CASI ) to Buy, target set at 4.

0 · Reply

BioTuesdays Sep. 2 at 5:07 PM

$CASI has announced the appointment of Barbara Krebs-Pohl, PhD, as an independent director to its board of directors (BOD). https://biotuesdays.com/2025/09/02/dr-barbara-krebs-pohl-joins-casis-bod/

0 · Reply

V9RDPUMA Aug. 31 at 12:49 PM

0 · Reply

TM555 Aug. 29 at 3:45 PM

$CASI predictable …

0 · Reply

TM555 Aug. 28 at 5:37 PM

$CASI hoping to see $3 soon

0 · Reply

SPYmyQQQ Aug. 28 at 2:06 PM

🚨 New Signal ✅ 💊 $CASI 🗓️ Aug 28, 2025 🎯 Entry: $2.3100 🎯 Target: $2.7667 (+19.77%)

0 · Reply

NakiaNodes Aug. 23 at 8:28 AM

$CASI CASI Pharmaceuticals Inc is facing commercialization challenges and regulatory uncertainty

0 · Reply

fromtheothersid3 Aug. 22 at 6:10 PM

$CASI 3,20 plus next week imho ☺️

0 · Reply

therealpicklerick Aug. 21 at 5:58 PM

$CASI slow crawl upwards

0 · Reply

therealpicklerick Aug. 20 at 5:51 PM

$CASI been holding since they announced fda clearance. $2.03 average. Holding for a nice Chinese pump

0 · Reply

fromtheothersid3 Aug. 20 at 4:39 PM

$CASI Beauty

0 · Reply

fromtheothersid3 Aug. 20 at 2:52 PM

$CASI building a sweet reversal Hammer 🔨

0 · Reply

TM555 Aug. 18 at 8:35 PM

$CASI was showing sell only. Earnings due soon. Hoping this points to

1 · Reply

Britishman1981 Aug. 18 at 8:25 PM

$CASI does anyone know when actual earnings are out

0 · Reply

Britishman1981 Aug. 18 at 1:50 PM

$CASI earnings out?

0 · Reply

Andy1995 Aug. 18 at 1:49 PM

$CASI

0 · Reply

therealpicklerick Aug. 18 at 1:44 PM

$CASI

0 · Reply

_www_larval_com_ Aug. 18 at 1:43 PM

$CRGO -12%[2%] $CASI 8%[-5%] $BTAI -6%[13%] $SYTA -5%[-8%] $OPEN 4%[18%] most notable movement within the first minutes of trading.

0 · Reply

SpartanVI Aug. 18 at 12:37 PM

$VTAK $CASI $IOBT $TIVC Vtak beautiful 🫡🛡

0 · Reply

DylanGFM Aug. 17 at 11:48 PM

$CASI if you change it to the weekly chart mb

0 · Reply

Market Cap	28.66M
Revenue (ttm)	28.54M
Net Income (ttm)	-39.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-137.56%
Debt to Equity Ratio	-0.92

Volume	38,500
Avg Vol	1,533,110
Day's Range	N/A - N/A
Shares Out	12.30M
Stochastic %K	39%
Beta	0.77
Analysts	Sell
Price Target	$4.00